Data Sheet 1_Feasibility of neoadjuvant immunochemotherapy in potentially resectable non-s

A single-arm meta-analysis synthesizing evidence from 34 studies involving 1,885 patients with potentially resectable stage IIB–IIIB non-small cell lung cancer. The study, authored by Feng Wu, evaluates the efficacy, pathological response rates, and frequency of treatment-related events associated with neoadjuvant immunochemotherapy. The analysis was conducted following PRISMA-NMA guidelines and includes data up to 9 December 2025.

Use Cases

• Assessing pooled surgical resection and pathological response rates based on the reported meta-analysis results.
• Evaluating the safety profile of neoadjuvant immunochemotherapy based on reported adverse event and surgical complication rates.
• Informing the design of randomized controlled trials based on the preliminary evidence and rationale provided in the conclusion.

Strengths

• Includes results from 34 studies and 1,885 patients, providing a substantial evidence base.
• Reports specific pooled rates with confidence intervals, such as a 76.0% surgical resection rate and a 35.9% pathological complete response rate.
• Follows PRISMA-NMA guidelines and includes sensitivity analyses and bias assessments, suggesting a structured methodology.

Limitations

• The dataset is a 28.0 KB document, indicating it contains summary results rather than raw patient-level data.
• The single-arm meta-analysis design lacks comparator data, limiting direct efficacy comparisons as noted in the conclusion.
• Column-level documentation is absent; field semantics must be inferred from the text.

Provenance

Source

figshare, author Fengpin Wu.

Collection Method

Systematic review and meta-analysis of studies from PubMed, Embase, and Cochrane databases.

Time Range

Studies searched up to 9 December 2025.

Freshness

Last updated 2026-05-07 04:45:44.